Evommune, Inc. (EVMN): R&D Expense
$74.04M
Year ended 2025-12-31
$88.69M
Trailing 12 months to 2026-09-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $74.04M | +15.3% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $64.24M | n/a | 2026-03-05, From 2024-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Evommune, Inc. (EVMN) | 2025-12-31 | $74.04M | +15.3% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $44.49M | +11.3% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $12.37M | -17.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $313.0K | -52.4% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $122.0K | +3.4% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $73.70M | +25.4% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $94.30M | -20.1% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $25.24M | -53.3% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $30.81M | +14.8% |
Compare EVMN, TNXP, PTN, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗